GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Cyclically Adjusted FCF per Share

Astellas Pharma (Astellas Pharma) Cyclically Adjusted FCF per Share : $0.70 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Astellas Pharma's adjusted free cash flow per share for the three months ended in Dec. 2023 was $0.139. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.70 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted FCF Growth Rate was 0.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Astellas Pharma was 10.80% per year. The lowest was 7.70% per year. And the median was 8.75% per year.

As of today (2024-04-30), Astellas Pharma's current stock price is $9.63. Astellas Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.70. Astellas Pharma's Cyclically Adjusted Price-to-FCF of today is 13.76.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Astellas Pharma was 28.14. The lowest was 14.83. And the median was 20.99.


Astellas Pharma Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted FCF per Share Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.74 0.85 0.78 0.77

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.77 0.70 0.67 0.70

Competitive Comparison of Astellas Pharma's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted Price-to-FCF falls into.



Astellas Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.139/106.8000*106.8000
=0.139

Current CPI (Dec. 2023) = 106.8000.

Astellas Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.146 95.700 0.163
201406 0.193 98.000 0.210
201409 0.129 98.500 0.140
201412 0.101 97.900 0.110
201503 0.021 97.900 0.023
201506 0.053 98.400 0.058
201509 0.224 98.500 0.243
201512 0.067 98.100 0.073
201603 0.437 97.900 0.477
201606 0.043 98.100 0.047
201609 0.273 98.000 0.298
201612 0.331 98.400 0.359
201703 0.157 98.100 0.171
201706 0.233 98.500 0.253
201709 0.203 98.800 0.219
201712 0.383 99.400 0.412
201803 0.404 99.200 0.435
201806 0.125 99.200 0.135
201809 0.304 99.900 0.325
201812 0.353 99.700 0.378
201903 0.176 99.700 0.189
201906 -0.015 99.800 -0.016
201909 0.357 100.100 0.381
201912 0.217 100.500 0.231
202003 0.152 100.300 0.162
202006 -0.058 99.900 -0.062
202009 0.426 99.900 0.455
202012 0.489 99.300 0.526
202103 0.313 99.900 0.335
202106 0.099 99.500 0.106
202109 0.349 100.100 0.372
202112 0.276 100.100 0.294
202203 0.143 101.100 0.151
202206 0.125 101.800 0.131
202209 0.266 103.100 0.276
202212 0.210 104.100 0.215
202303 0.358 104.400 0.366
202306 -0.016 105.200 -0.016
202309 0.022 106.200 0.022
202312 0.139 106.800 0.139

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Astellas Pharma  (OTCPK:ALPMY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=9.63/0.7
=13.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Astellas Pharma was 28.14. The lowest was 14.83. And the median was 20.99.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Astellas Pharma Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (Astellas Pharma) Headlines